Two Cases of Anti-PD1 Antibody Associated Neurological Immune-Related Adverse Effects

被引：0
|
作者：
Vitek, Grace [1 ]
Hansra, Harjot [2 ]
机构：
[1] Creighton Univ, Sch Med, Omaha, NE USA
[2] Dignity Hlth, Barrow Neurol Inst, San Francisco, CA USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000203811
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P5-4.001
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Immune-related adverse events with resumed anti-PD-1 therapy
    Reactions Weekly, 2017, 1676 (1) : 4 - 4
  • [12] Immune-related adverse event recurrence with anti-PD-1 therapy
    Reactions Weekly, 2020, 1816 (1) : 8 - 8
  • [13] Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
    Eigentler, Thomas K.
    Hassel, Jessica C.
    Berking, Carola
    Aberle, Jens
    Bachmann, Oliver
    Gruenwald, Viktor
    Kaehler, Katharina C.
    Loquai, Carmen
    Reinmuth, Niels
    Steins, Martin
    Zimmer, Lisa
    Sendl, Anna
    Gutzmer, Ralf
    CANCER TREATMENT REVIEWS, 2016, 45 : 7 - 18
  • [14] RISK FACTORS OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB
    Eun, Y.
    Kim, I. Y.
    Kim, H.
    Ahn, J. K.
    Park, E. -J.
    Hwang, J.
    Jeong, H.
    Chai, J. Y.
    Cha, H. -S.
    Koh, E. -M.
    Lee, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1205 - 1205
  • [15] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
    Pollack, M. H.
    Betof, A.
    Dearden, H.
    Rapazzo, K.
    Valentine, I.
    Brohl, A. S.
    Ancell, K. K.
    Long, G. V.
    Menzies, A. M.
    Eroglu, Z.
    Johnson, D. B.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 250 - 255
  • [16] Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?
    Barp, Andrea
    Gilardin, Laurent
    Afanasiev, Vadim
    Delorme, Cecile
    Viala, Karine
    Bernard, Sophie
    Brice, Pauline
    Psimaras, Dimitri
    Lenglet, Timothee
    LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 547 - 549
  • [17] Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
    Ellebaek, E.
    Jurlander, R. S.
    Guldbrandt, L. M.
    Holmstroem, R. B.
    Donia, M.
    Haslund, C. A.
    Schmidt, H.
    Bastholt, L.
    Ruhlmann, C. H.
    Svane, I-M.
    ANNALS OF ONCOLOGY, 2023, 34 : S690 - S690
  • [18] Correlation between immune-related adverse events and treatment efficacy of anti-PD1 immunotherapy in patients with esophageal squamous cell carcinoma
    Cao, Ruijie
    Wu, Chensi
    Lv, Yalei
    Xu, Shuo
    Li, Cuizhen
    Yin, Fei
    Li, Jing
    ONCOLOGY LETTERS, 2023, 25 (02)
  • [19] Immune-related adverse events (irAEs) predict therapeutic efficacy of an anti-PD-1 antibody in cancer patients
    Rogado, J.
    Romero Laorden, N.
    Sanchez Torres, J. M.
    Ballesteros Garcia, A. I.
    Pacheco-Barcia, V. E.
    Arranz, R.
    Mondejar Solis, R.
    Gullon, P.
    Lorenzo, A.
    Colomer Bosch, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [20] Unexpected serious ocular and neurological immune-related adverse events in a patient treated with the anti-PD-L1 durvalumab
    Olivier, P.
    Larrieu-Ciron, D.
    Fabre, A.
    Mounier, M.
    Montastruc, J. L.
    Pouessel, D.
    Moyal, E. Cohen-Jonathan
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 63 - 63
12345